MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

Kodu・Aktsiate loetelu・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Avatud

1.35 3.05

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.31

Max

1.3599999999999999

Põhinäitajad
By Trading Economics
Sissetulek	2.7M -24M
Aktsiakasum	-0.354
Töötajad	49
EBITDA	-5.3M -28M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+102.27% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	7. mai 2026

Turustatistika
By TradingEconomics
Turukapital	-8.4M 73M
Eelmine avamishind	-1.7
Eelmine sulgemishind	1.35

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

1.43 / 1.6 Toetus ja vastupanu

Pliant Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

2. apr 2026, 17:11 UTC

Suurimad hinnamuutused turgudel

Uudisväärsed sündmused

Home Depot Shares Hit 52-Week Low as Iran War Threatens Housing Rebound

2. apr 2026, 17:10 UTC

Uudisväärsed sündmused

ECB's Next Move Likely a Rate Rise, But Timing Unclear Amid Iran War, Villeroy Says

3. apr 2026, 00:00 UTC

Uudisväärsed sündmused

How Insulated Is the U.S. Economy From the Iran War? -- WSJ

2. apr 2026, 23:47 UTC

Market Talk

Uudisväärsed sündmused

Nikkei Might Rise After Thursday's Selloffs -- Market Talk

2. apr 2026, 21:05 UTC

Omandamised, ülevõtmised, äriostud

Starbucks: Under the Terms of the Agreement, Funds Managed by Boyu Cap Now Hold a 60% Stake in Starbucks China Retail Ops >SBUX

2. apr 2026, 21:05 UTC

Omandamised, ülevõtmised, äriostud

Starbucks: Retains 40% Ownership Interest and Continues to Own and License the Brand and Intellectual Property to JV >SBUX

2. apr 2026, 21:05 UTC

Omandamised, ülevõtmised, äriostud

Starbucks: Joint Venture Is Designed to Enhance Starbucks Ability to Expand Footprint, Deepen Local Relevance >SBUX

2. apr 2026, 21:05 UTC

Omandamised, ülevõtmised, äriostud

Starbucks and Boyu Cap: Finalize Joint Venture to Accelerate Long-Term Growth in China

2. apr 2026, 21:01 UTC

Uudisväärsed sündmused

Investors Waver after Trump Speech on Iran, Ending Two-Day Surge in Stocks -- WSJ

2. apr 2026, 20:59 UTC

Omandamised, ülevõtmised, äriostud

Starbucks and Boyu Capital Finalize China JV

2. apr 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

2. apr 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

2. apr 2026, 20:41 UTC

Tulu

These Stocks Are Today's Movers: Tesla, Globalstar, Blue Owl, United Airlines, Carnival, Lumentum, and More -- Barrons.com

2. apr 2026, 20:32 UTC

Market Talk

Higher Gas Prices Intensify K-Shaped Economy -- Market Talk

2. apr 2026, 20:30 UTC

Omandamised, ülevõtmised, äriostud

SBA Communications Stock Jumps on Report of Sale Talks -- Barrons.com

2. apr 2026, 20:09 UTC

Market Talk

Eli Lilly On More Equal Footing With Rival With Weight-Loss Pill -- Market Talk

2. apr 2026, 20:01 UTC

Omandamised, ülevõtmised, äriostud

SBA Communications Stock Jumps on Report of Sale Talks -- Barrons.com

2. apr 2026, 19:46 UTC

Market Talk

Is Oil the New GameStop? -- Market Talk

2. apr 2026, 19:35 UTC

Market Talk

U.S. Natural Gas Falls As Storage Injection Season Gets Under Way -- Market Talk

2. apr 2026, 19:29 UTC

Omandamised, ülevõtmised, äriostud

SBA Communications Stock Jumps on Report of Sale Talks -- Barrons.com

2. apr 2026, 19:24 UTC

Market Talk

Uudisväärsed sündmused

Oil Futures Jump Ahead of Long Weekend -- Market Talk

2. apr 2026, 19:20 UTC

Market Talk

Nike Has Yet to Show That a Turnaround is on Horizon -- Market Talk

2. apr 2026, 19:01 UTC

Omandamised, ülevõtmised, äriostud

Union Pacific: ATDA Agreement to Guarantee Jobs for Life for Union Employees After Norfolk Southern Deal

2. apr 2026, 19:00 UTC

Omandamised, ülevõtmised, äriostud

Union Pacific: Agreement Reached With American Train Dispatchers Association

2. apr 2026, 18:24 UTC

Omandamised, ülevõtmised, äriostud

Globalstar Stock Rises on Amazon Deal Report. Why Apple Could Scuttle the Launch. -- Barrons.com

2. apr 2026, 17:44 UTC

Market Talk

Uudisväärsed sündmused

Oil Supply Squeeze Puts Refiners in a Quandary -- Market Talk

2. apr 2026, 17:32 UTC

Uudisväärsed sündmused

Amazon to Boost Fuel Surcharges on Third-Party Sellers as Costs Rise -- Barrons.com

2. apr 2026, 17:26 UTC

Tulu

These Stocks Are Today's Movers: Tesla, Globalstar, Blue Owl, United Airlines, Carnival, Lumentum, and More -- Barrons.com

2. apr 2026, 17:17 UTC

Market Talk

Shares of Canadian Exports Heading to U.S. Continues to Slide -- Market Talk

2. apr 2026, 17:09 UTC

Market Talk

Uudisväärsed sündmused

Oil Holds Gains After Trump Speech Disappointed Market -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Pliant Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

102.27% tõus

12 kuu keskmine prognoos

Keskmine 2.67 USD 102.27%

Kõrge 3 USD

Madal 2 USD

Põhineb 5 Wall Streeti analüütiku instrumendi Pliant Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

5 ratings

Osta

Hoia

Müü

Põhineb 5 analüütiku instrumendi Pliant Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

1.43 / 1.6Toetus ja vastupanu

Recent bearish events outweigh bullish events.

There is one bearish event.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.